Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,261 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,261 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05648188 | A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells(LUNGadenosine) | — | withdrawn | Dec 13, 2022 | Centre Hospitalier Universitaire de Nice | no patients enrolled | Enrollment / accrual |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced… | Phase 1 | terminated | Nov 25, 2016 | Allist Pharmaceuticals, Inc. | Indications have been approved for marketing | Other (stated, no rule matched) |
| NCT03127449 | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | N/A | terminated | Apr 25, 2017 | Allist Pharmaceuticals, Inc. | Indications have been approved for marketing | Other (stated, no rule matched) |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04512430 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | Phase 2 | terminated | Aug 13, 2020 | Fundación GECP | Low recruitment | Enrollment / accrual |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line…(CONTERNO) | Phase 3 | terminated | Mar 8, 2021 | Checkpoint Therapeutics, Inc. | Regional political conflict | Other (stated, no rule matched) |
| NCT05911308 | Abequolixron (RGX-104) and Durvalumab in Lung Cancer | Phase 1 | terminated | Jun 22, 2023 | UNC Lineberger Comprehensive Cancer Center | Sponsor is closing the trial. | Other (stated, no rule matched) |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | Phase 1 | terminated | Aug 4, 2021 | Nouscom SRL | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Phase 1 / Phase 2 | terminated | Sep 24, 2019 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and… | Phase 1 / Phase 2 | terminated | Sep 16, 2022 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | Phase 3 | terminated | Mar 20, 2020 | Peter MacCallum Cancer Centre, Australia | Not meeting recruitment timelines | Enrollment / accrual |
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | Phase 1 | withdrawn | Jul 12, 2021 | Allist Pharmaceuticals, Inc. | The protocol need to review | Other (stated, no rule matched) |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04032847 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | Phase 1 / Phase 2 | terminated | Jul 25, 2019 | Achilles Therapeutics UK Limited | Sponsor decision | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT00503971 | Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR… | Phase 1 / Phase 2 | terminated | Jul 19, 2007 | Spanish Lung Cancer Group | not stated | Not stated |
| NCT00979576 | BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Sep 18, 2009 | Boehringer Ingelheim | not stated | Not stated |
| NCT03496766 | Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS | Phase 2 | terminated | Apr 12, 2018 | Spanish Lung Cancer Group | The recruitment was closed prematurely to due to slow recruitment. | Enrollment / accrual |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer… | Phase 2 | terminated | Aug 3, 2020 | Emory University | This study was terminated after interim analyses showed no benefits. | Efficacy / futility |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT… | Phase 2 | withdrawn | Jul 2, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With… | Phase 3 | terminated | Sep 4, 2014 | Boehringer Ingelheim | not stated | Not stated |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Phase 1 | terminated | Apr 28, 2021 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Phase 1 | terminated | Feb 16, 2022 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05407038 | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer… | N/A | terminated | Jun 7, 2022 | Mayo Clinic | Study stopped early due to enrollment challenges. | Enrollment / accrual |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT06075615 | A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has… | — | withdrawn | Oct 10, 2023 | Pfizer | Sponsor Decision | Sponsor / business decision |
| NCT04474613 | Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at… | N/A | terminated | Jul 17, 2020 | Case Comprehensive Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03371381 | An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes… | Phase 1 / Phase 2 | terminated | Dec 13, 2017 | Janssen Research & Development, LLC | Development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical… | Efficacy / futility |
| NCT02592967 | Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria… | Phase 1 | terminated | Oct 30, 2015 | Janssen Research & Development, LLC | Development of JNJ-64041757 discontinued due to lack of efficacy. No further follow up data will be… | Efficacy / futility |
| NCT02887521 | Pulmonary Rehabilitation Before Lung Cancer Resection | Phase 3 | terminated | Sep 2, 2016 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT03705403 | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study(IMMUNOSABR2) | Phase 2 | terminated | Oct 15, 2018 | Maastricht University Medical Center | This trial is not transitioning to the Clinical Trial Regulation (CTR) EU No 536/2014. | Other (stated, no rule matched) |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | Phase 1 | terminated | May 14, 2019 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | Phase 1 | terminated | Jun 7, 2021 | The Netherlands Cancer Institute | Due to a lack of safety and efficacy. | Safety / toxicity |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | Phase 1 | withdrawn | Nov 8, 2024 | Astellas Pharma Global Development, Inc. | A business decision was made to not initiate this study. | Sponsor / business decision |
| NCT04856176 | A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with… | Phase 2 | terminated | Apr 23, 2021 | Tufts Medical Center | Futility | Efficacy / futility |
| NCT04923776 | Liver Directed RT + Chemo-immunotherapy for ES-SCLC | Phase 2 | terminated | Jun 11, 2021 | Brian Henick, MD | Poor enrollment | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04889066 | Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small… | Phase 2 | withdrawn | May 17, 2021 | University of Texas Southwestern Medical Center | Project Never Initiated since sponsor stopped support for the trial- no human subjects were… | Enrollment / accrual |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT05094544 | Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC(POIMS) | N/A | withdrawn | Oct 26, 2021 | University of Kansas Medical Center | No participants enrolled | Enrollment / accrual |
| NCT05375084 | SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small… | Phase 1 | terminated | May 16, 2022 | Navire Pharma Inc., a BridgeBio company | Business reasons | Sponsor / business decision |
| NCT05480865 | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid…(Argonaut) | Phase 1 | terminated | Jul 29, 2022 | Navire Pharma Inc., a BridgeBio company | Business Reasons | Sponsor / business decision |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1… | Phase 1 / Phase 2 | terminated | Jun 25, 2021 | Astellas Pharma Global Development, Inc. | The comprehensive assessment of other studies indicated the lack of significant monotherapy… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 10, 2025source: clinicaltrials